Negotiations Will Occur in 2026 With Negotiated Prices Effective in 2028Continue reading
Category Archives: Advocacy and Regulations
U of A expert urges for more comprehensive telehealth policy
Six years after the COVID pandemic, the virtues of remote health care are clear: Allowing patients to visit with their providers via phone or video call often means better access to health care for patients, including those in rural communities and those who struggle to leave their homes.
But the laws that regulate telehealth, as it’s known, have not kept pace with its rise and demand – at least not in the form of comprehensive legislation. Since the pandemic, Congress has funded telehealth largely on a stopgap basis, temporarily extending COVID-era flexibilities more than a dozen times in the last few years. Each time, the extension provides only temporary funding to the Centers for Medicare and Medicaid Services – the nation’s largest funder of telehealth services.
The newest deadline for Congress to act on telehealth policy – the 15th deadline set on this issue since the COVID pandemic – is Jan. 30.Continue reading
Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings
WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.
AZBio Celebrates Trailblazers 2025
AZBio and members of the Arizona Business and Bioscience Community came together honor Arizona Legislators and State and Local Elected Officials who have made it possible for the Arizona Bioscience Industry to gain national recognition, build capital infrastructure, and take its place as a leader in both scientific discovery and job growth.Continue reading
Barby Ingle Appointed Biopharma Rep to Arizona Rare Disease Advisory Council
PHOENIX, Ariz. – October 29, 2025 – Barby Ingle is a chronic pain educator, best-selling author, and patient advocate. Arizona Senate President Warren Petersen has appointed Mrs. Ingle to the newly formed Arizona Rare Disease Advocacy Council. Her role is Biopharma Representative on the Arizona Rare Disease Advisory Council (RDAC). This recognizes her expertise in rare disease advocacy and industry. It also honors her dedication to improving access to care for underserved patients.
FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
WASHINGTON— OCTOBER 29, 2025 — The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.Continue reading
New Online Resource Spotlights Life Science Investments in Arizona and Across the U.S.
We Work For Health is tracking every new U.S. biopharma facility announcement and news report, revealing more than $425 billion being invested to drive new R&D, expand manufacturing and create jobs nationwide. The continually updated database is accessible below through a state map of announcements that mention specific cities or states and also a tracker of every public commitment since January 2025.Continue reading
Amgen Makes Repatha® Available Through AMGENNOW, A Direct-to-Patient Program in the U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price
THOUSAND OAKS, Calif. Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.Continue reading
FDA Announces New ANDA Prioritization Pilot to Support U.S. Generic Drug Manufacturing and Testing
[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading
Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals
President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759Continue reading